NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Reducing Risk of Dementia Through Deprescribing

CompletedNA

Sponsor: Indiana University

Conditions: Dementia, Alzheimer Disease, Late Onset

Interventions: Deprescribing of target anticholinergics, Usual Care

Countries: United States

A cluster-randomized controlled trial (RCT) called "Reducing Risk of Dementia through Deprescribing" (R2D2) to evaluate the impact of a deprescribing intervention on important cognitive and safety outcomes.

Eligibility overview

Sex: ALL

Age: 65 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria for Participants:

* Age 65 and older;
* At least one office visit to their primary care physician within the previous 12 months;
* Use of a target anticholinergic medication within the last two weeks OR medical record evidence of exposure to target anticholinergic medications at or above a cognitive risk threshold in the prior 12 months
* Able to communicate in English;
* Access to a telephone

Exclusion Criteria for Participants:

* Permanent resident of an extended care facility (nursing home)
* Diagnosis of schizophrenia, bipolar disorder, or schizoaffective disorder defined by International Classification of Diseases (ICD) version 9/10 codes
* Diagnosis of Alzheimer's Disease or Related Dementia as determined by (a), (b), or (c) below:

  1. ICD-9/10 codes, or
  2. Current use of a medication for Alzheimer's Disease or a Related Dementia, or
  3. A pattern of responses to the Functional Activities Questionnaire (FAQ) that indicate dementia (i.e., ≥ 3 FAQ items are scored at "requires assistance," or if ≥ 1 FAQ item is scored at "dependent").

Locations (2)

Indianapolis, Indiana, United States
Indianapolis, Indiana, United States